{"title":"罗氏与爱思利康合作加强对中国HCV市场的关注","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I4.1927","DOIUrl":null,"url":null,"abstract":"Roche has partnered with the US- and China-based speciality pharmaceutical company Ascletis for the development and commercialisation of its hepatitis C virus (HCV) protease inhibitor danoprevir in China. At present, no direct-acting antiviral agents are available for the treatment of HCV in the country. Roche acquired the drug candidate from InterMune in 2010 and subsequently chose to pursue its development as an add-on therapy to Pegasys® (peginterferon alpha-2a) in emerging markets. Ascletis will fund and be responsible for the development, regulatory affairs and manufacturing of danoprevir in greater China, including Taiwan, Hong Kong and Macau.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"230 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Roche Sharpens its Focus on Chinese HCV Market with Ascletis Collaboration\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2013I4.1927\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Roche has partnered with the US- and China-based speciality pharmaceutical company Ascletis for the development and commercialisation of its hepatitis C virus (HCV) protease inhibitor danoprevir in China. At present, no direct-acting antiviral agents are available for the treatment of HCV in the country. Roche acquired the drug candidate from InterMune in 2010 and subsequently chose to pursue its development as an add-on therapy to Pegasys® (peginterferon alpha-2a) in emerging markets. Ascletis will fund and be responsible for the development, regulatory affairs and manufacturing of danoprevir in greater China, including Taiwan, Hong Kong and Macau.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"230 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-04-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2013I4.1927\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I4.1927","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Roche Sharpens its Focus on Chinese HCV Market with Ascletis Collaboration
Roche has partnered with the US- and China-based speciality pharmaceutical company Ascletis for the development and commercialisation of its hepatitis C virus (HCV) protease inhibitor danoprevir in China. At present, no direct-acting antiviral agents are available for the treatment of HCV in the country. Roche acquired the drug candidate from InterMune in 2010 and subsequently chose to pursue its development as an add-on therapy to Pegasys® (peginterferon alpha-2a) in emerging markets. Ascletis will fund and be responsible for the development, regulatory affairs and manufacturing of danoprevir in greater China, including Taiwan, Hong Kong and Macau.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
